Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Tillväxt- och utvecklingsrelaterade resultat hos barn med transfusionsberoende beta-talassemi efter genterapi

2 november 2026 uppdaterad av: Jun Shi, Institute of Hematology & Blood Diseases Hospital, China

Tillväxt och utveckling, hälsorelaterad livskvalitet för barn med transfusionsberoende beta-talassemi efter genterapi

The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who have received gene therapy, TDT children with lifelong supportive therapy and healthy children.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Observationell

Inskrivning (Beräknad)

100

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina
        • Rekrytering
        • Regenerative Medicine Center
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

3 år till 14 år (Barn)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Participants are divided into three groups: TDT children who have received gene therapy, TDT children who have received lifelong supportive therapy, and healthy children.

Beskrivning

Inclusion Criteria:

Gene therapy group-inclusion

  • Male or female age of 3-14 years
  • TDT Children who have received gene therapy.
  • Subjects who are willing and able to provide written informed consent.

Supportive therapy group-inclusion

  • Gender same as the matched case
  • Age similar to the matched case
  • Children with β-TDT
  • No history of gene therapy or allogeneic hematopoietic stem cell transplantation
  • Subjects who are willing and able to provide written informed consent.

Healthy children group-inclusion

  • Gender same as the matched case
  • Age similar to the matched case
  • Subjects who are willing and able to provide written informed consent.

Exclusion Criteria:

  • Diagnosis of compound α-thalassemia
  • Uncontrolled systemic fungal, bacterial, or viral infection
  • History of malignant solid tumors, myeloproliferative or immunodeficiency diseases
  • Diagnosed with mental illness
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above

Discontinuation of Study :

  • Subjects who are unwilling or unable to continue participating in the study (withdrawal of informed consent) may withdraw from the study
  • Subjects who received gene therapy or allogeneic hematopoietic stem cell transplantation during the study
  • The subject is seriously non-compliant with the study requirements, such as missing 2 consecutive visits
  • Subject lost to follow-up

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Gene therapy group

TDT Children who have received gene therapy between 3~14 years old.

Autologous edited hematopoietic stem cell transplantation

Supportive therapy group

TDT Children who received lifelong treatment with blood transfusions and iron chelation. They were selected based on the age and sex of the gene therapy group.

Healthy children group

Healthy children were selected based on the age and sex of the gene therapy group.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Growth in pediatric subjects will be assessed by height.
Tidsram: Up to 5 years.

Height in meters.

Up to 5 years.
Growth in pediatric subjects will be assessed by weight.
Tidsram: Up to 5 years.

Weight in kilograms.

Up to 5 years.
Growth in pediatric subjects will be assessed by bone density.
Tidsram: Up to 5 years.

Bone density measurement is measured by a procedure called densitometry, performed in the radiology medicine departments of hospitals or clinics. The result is the bone mineral density in grams per unit area (g/cm2).

Up to 5 years.
The pubertal status will be measured using by Tanner scale.
Tidsram: Up to 5 years.

The Tanner scale, a well-known technique used to define pubertal stage, is based on physical measurements of development based on external primary and secondary sex characteristics (from Tanner 1: pre-pubertal to Tanner 5: mature adolescent).It was developed by Marshall and Tanner while conducting a longitudinal study during the 1940s to the 1960s in England. Based on observational data, they developed separate scales for the development of external genitalia: phallus, scrotum, and testes volume in males; breasts in females; and pubic hair in both males and females.

Up to 5 years.
Quality of life will be measured using by Pediatric Quality of Life Inventory (PedsQL) at baseline and the end of the study.
Tidsram: Up to 5 years.

The Pediatric Quality of Life Inventory (PedsQL) is a valid, standardized, generic, and self-reporting assessment tool to measure health-related quality of life HRQOL for pediatrics and adolescents. PedsQL contain 23-items, and consists of the following: physical functioning, emotional functioning, social functioning, and school functioning. Each item is scored on a 5-point scale, scores are linearly transformed to a 0-100 scale in which high score means better condition.

Up to 5 years.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 juni 2023

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

27 juli 2023

Först inskickad som uppfyllde QC-kriterierna

6 augusti 2023

Första postat (Faktisk)

14 augusti 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera